Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This Phase I/II trial studies the safety and effectiveness of lenalidomide with or without
idelalisib. Biological therapies, such as lenalidomide, may stimulate the immune system in
different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
lenalidomide is more effective with or without idelalisib in treating mantle cell lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Biologics, Inc. Celgene Corporation Gilead Sciences National Cancer Institute (NCI)